SOURCE: Equity News Circuit

Equity News Circuit

April 25, 2013 08:45 ET

Free Research Reports on HSTM, IIVI, IRWD and SCMP Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - Apr 25, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

HealthStream, Inc. (NASDAQ: HSTM) shares surged 16.19 percent on more than double the average daily volume Tuesday to close at $23.54 a share. The company reported net income of $1.9 million, or $0.07 per share, for the first quarter of 2013, and increase of 36 percent when compared to the year ago quarter.

Find out more about HealthStream including full access to the free equity report at: www.BedfordReport.com/HSTM

II-VI, Inc. (NASDAQ: IIVI) shares declined 12.03 percent on volume of nearly 2.0 million shares traded Tuesday to close at $14.85. The company guidance for full-year EPS to be in the range of $0.84 to $0.89 on revenues of $550 to $555 million fell short of Wall Street's estimates.

Find out more about II-VI including full access to the free equity report at: www.BedfordReport.com/IIVI

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares declined 6.26 percent on more than three times the average daily volume Tuesday to close at $16.77 a share. The company's loss grew to $93.9 million, or $0.87 per share, for the first quarter of 2013, compared to a loss of $35.6 million, or $0.34 per share, a year prior.

Find out more about Ironwood Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/IRWD

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) shares soared 24.05 percent on volume of 1.34 million shares traded Tuesday to close at $8.46. The company announced that the FDA has approved Amitiza for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

Find out more about Sucampo Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/SCMP

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information